Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection
Open Access
- 15 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 203 (8), 1063-1072
- https://doi.org/10.1093/infdis/jiq168
Abstract
Influenza A virus infections impose a recurrent and global disease burden. Current antivirals against influenza are not always effective. We assessed the protective potential of monovalent and bivalent Nanobodies (Ablynx) against challenge with this virus. These Nanobodies were derived from llamas and target H5N1 hemagglutinin. Intranasal administration of Nanobodies effectively controlled homologous influenza A virus replication. Administration of Nanobodies before challenge strongly reduced H5N1 virus replication in the lungs and protected mice from morbidity and mortality after a lethal challenge with H5N1 virus. The bivalent Nanobody was at least 60-fold more effective than the monovalent Nanobody in controlling virus replication. In addition, Nanobody therapy after challenge strongly reduced viral replication and significantly delayed time to death. Epitope mapping revealed that the VHH Nanobody binds to antigenic site B in H5 hemagglutinin. Because Nanobodies are small, stable, and simple to produce, they are a promising, novel therapeutic agent against influenza.Keywords
This publication has 45 references indexed in Scilit:
- Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic DriftScience, 2009
- Antibody Recognition of a Highly Conserved Influenza Virus EpitopeScience, 2009
- Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virusProceedings of the National Academy of Sciences of the United States of America, 2009
- Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplificationNucleic Acids Research, 2008
- Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virusProceedings of the National Academy of Sciences of the United States of America, 2008
- Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategiesProceedings of the National Academy of Sciences of the United States of America, 2008
- Inhibition of the cytokine response does not protect against lethal H5N1 influenza infectionProceedings of the National Academy of Sciences of the United States of America, 2007
- Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptorsNature, 2006
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005